menu
    • menu

    Company profile for GeNeuro

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    GeNeuro is a clinical stage pharmaceutical company developing a new approach to the treatment of autoimmune diseases, including multiple sclerosis (MS) and Type 1 Diabetes (T1D) associated with pathogenic proteins expressed by human endogenous retroviruses (HERV), viral genes that account for 8% of human DNA. This novel approach is the result of 25 years of research on endogenous retroviruses, including 15 within Institut Mé...
    GeNeuro is a clinical stage pharmaceutical company developing a new approach to the treatment of autoimmune diseases, including multiple sclerosis (MS) and Type 1 Diabetes (T1D) associated with pathogenic proteins expressed by human endogenous retroviruses (HERV), viral genes that account for 8% of human DNA. This novel approach is the result of 25 years of research on endogenous retroviruses, including 15 within Institut Mérieux and INSERM, before the creation of GeNeuro in 2006. This research has allowed us to uncover and understand the action of a factor potentially causative of multiple sclerosis, the envelope protein (Env).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GeNeuroSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    3, Chemin du Pré-Fleuri CH-1228 Plan-les-Ouates Geneva
    Telephone
    Telephone
    +41 22 552 48 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.geneuro.ch/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    GeNeuro's long COVID trial fails, triggering layoffs
    GeNeuro's long COVID trial fails, triggering layoffs

    28 Jun 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/geneuros-long-covid-trial-fails-triggering-layoffs-and-search-strategic-alternatives

    FIERCE BIOTECH
    28 Jun 2024
    Share Share
    Data Monitoring Committee Recommends Continuing the Trial Evaluating Temelimab
    Data Monitoring Committee Recommends Continuing the Trial Evaluating Temelimab

    11 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231210164670/en

    BUSINESSWIRE
    11 Dec 2023
    Share Share
    GeNeuro and Verily Collaborate to Advance Long-COVID Research
    GeNeuro and Verily Collaborate to Advance Long-COVID Research

    19 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231018254904/en

    BUSINESSWIRE
    19 Oct 2023
    Share Share
    GeNeuro Announces Recruitment of Patient in Centers in Trial Assessing Temelimab
    GeNeuro Announces Recruitment of Patient in Centers in Trial Assessing Temelimab

    16 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221116005201/en

    BUSINESSWIRE
    16 Nov 2022
    Share Share
    Geneuro Receives CHF 6.7M in Funding to Develop Temelimab Against Long-COVID
    Geneuro Receives CHF 6.7M in Funding to Develop Temelimab Against Long-COVID

    13 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211212005176/en

    BUSINESSWIRE
    13 Dec 2021
    Share Share
    GeNeuro announces agreement to assess W-ENV and long-Covid syndromes
    GeNeuro announces agreement to assess W-ENV and long-Covid syndromes

    27 Sep 2021

    // PHARMACEUTICAL-TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/geneuro-agreement-long-covid/

    PHARMACEUTICAL-TECHNOLOGY
    27 Sep 2021
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search